Previous 10 | Next 10 |
knowlesgallery/iStock via Getty Images The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online. As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to...
CAMBRIDGE, Mass., July 23, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced it will share multiple oral and poster presentations from its Alzheimer’s disease clinical development portfolio at the Alzheimer’s Association International Conference (AAIC), w...
Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...
The following slide deck was published by Biogen Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Biogen Inc. 2021 Q2 - Results - Earnings Call Presentation
Image source: The Motley Fool. Biogen inc (NASDAQ: BIIB) Q2 2021 Earnings Call Jul 22, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Biogen inc (BIIB) Q2 2021 Earnings Call Transcript
Biogen ( NASDAQ: BIIB ) launched in June a new Alzheimer’s disease drug but its uptake so far has been slow, leading one notable Wall Street analyst to recommend a cautious approach towards the stock. Cost of Biogen’s Alzheimer’s treatment criticized The...
Biogen Inc. (BIIB) Q2 2021 Earnings Conference Call July 22, 2021 8:00 AM ET Company Participants Michel Vounatsos – Chief Executive Officer Mike Hencke – Director, Investor Relations Al Sandrock – Executive Vice President-Research & Development Mike McDonnell –...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips India Globalization Capital (NYSE: IGC ) is up monumentally today. The company appears to be taking a leap further into the world of biotech with its newest announcement. It appears IGC stock is being boosted by ...
CharlieAJA/iStock via Getty Images Despite declining sales in its key therapeutics in the portfolio, Biogen (BIIB) has raised the full-year revenue forecast on the back of recent FDA approval of the company’s Alzheimer’s medication, Aduhelm. Biogen shares have added ~1.4%...
NOTE: ADUHELM TM (aducanumab-avwa) injection 100 mg/mL solution is indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which tr...
News, Short Squeeze, Breakout and More Instantly...
Efforts focused on four areas: access and health equity, workforce and DE&I, community impact and the environment CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023 Corporate Responsibility Report detailing pro...
Corporate earnings came to the market’s rescue in the past week, helping to overcome rate fears. As we look ahead to the unfolding week, it r...
Biogen Inc (NASDAQ:BIIB) reported better-than-expected earnings for its first quarter on Wednesday. Biogen reported first-quarter adjusted EPS of $...